Benign Prostatic Hyperplasia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharma, GSK

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast

Some of the key facts of the Benign Prostatic Hyperplasia Market Report: 

• The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2022, Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas) and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics
• In December 2021, Veru announced FDA Approval of ENTADFI, a new treatment for Benign Prostatic Hyperplasia.
• According to a study by Boyle et al. (n.d.), up to 60% of men over 60 may have hypertension, and 50% of men over 60 may have symptoms consistent with BPH. This suggests that even if their aetiologies are unrelated and they develop independently, at least one-eighth of all men over the age of 60 develop both symptomatic BPH and hypertension
• The most anticipated new treatments are Vibegron (Urovant Sciences) and DKF-313 (Dongkook Pharmaceutical), which are waiting for approval. In a phase II clinical trial, the novel medication AUS-131 from Ausio Pharmaceuticals was examined
• Obesity, heart and circulatory disease, type 2 diabetes, an increase in the geriatric population, and the anticipated approval of novel therapies like Vibegron (Urovant Sciences), DKF-313 (Dongkook Pharmaceutical), and AUS-131 (Ausio Pharmaceuticals) are the main factors driving the Benign Prostatic Hyperplasia market
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• The Benign Prostatic Hyperplasia epidemiology based on age-specific cases analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years
• The Benign Prostatic Hyperplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

Benign Prostatic Hyperplasia Overview

Men who have BPH, also known as benign prostatic hyperplasia, have enlarged prostates that are not malignant. Other names for benign prostatic hyperplasia are benign prostatic blockage and benign prostatic hypertrophy. The urethra is pinched and pressed against by the prostate as it grows in size. Bladder wall thickness increases.

Get a Free sample for the Benign Prostatic Hyperplasia Market Report 

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market

Benign Prostatic Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Benign Prostatic Hyperplasia Epidemiology Segmentation:

The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Benign Prostatic Hyperplasia
• Prevalent Cases of Benign Prostatic Hyperplasia by severity
• Gender-specific Prevalence of Benign Prostatic Hyperplasia
• Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Benign Prostatic Hyperplasia Therapies and Key Companies

• DKF0313: Dongkook Pharmaceutical
• Vibegron: Urovant Sciences
• AUS-131 (S-equo): Ausio Pharmaceuticals
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharma
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Silodosin: JW Pharmaceutical
• Levitra (Vardenafil, BAY38-9456): Bayer
• WC3055: Warner Chilcott
• Afalaza: Materia Medica Holding
• S-equol: Ausio Pharma
• MK0906: Organon and Co
• NX-1207: Nymox Corporation
• Tamsulosin: GlaxoSmithKline

Discover more about therapies set to grab major Benign Prostatic Hyperplasia market share @ Benign Prostatic Hyperplasia Treatment Market

Scope of the Benign Prostatic Hyperplasia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement 

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Benign Prostatic Hyperplasia Market Report Introduction

2. Executive Summary for Benign Prostatic Hyperplasia

3. SWOT analysis of Benign Prostatic Hyperplasia

4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance

5. Benign Prostatic Hyperplasia Market Overview at a Glance

6. Benign Prostatic Hyperplasia Disease Background and Overview

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Prostatic Hyperplasia 

9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices

10. Benign Prostatic Hyperplasia Unmet Needs

11. Benign Prostatic Hyperplasia Emerging Therapies

12. Benign Prostatic Hyperplasia Market Outlook

13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2019–2032)

14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies

15. Benign Prostatic Hyperplasia Market Drivers

16. Benign Prostatic Hyperplasia Market Barriers

17.  Benign Prostatic Hyperplasia Appendix

18. Benign Prostatic Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services